Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

Nature cancer·2026
Same author

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

Blood advances·2026
Same author

Depletion of CD8<sup>+</sup> CART cells leads to superior anti-tumor efficacy of pure CD4<sup>+</sup> CART cells against acute leukemias.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response.

Transfusion·2026
Same author

Real-world experience with tabelecleucel within and beyond the approval label.

Blood advances·2026
Same author

Reshaping CAR-T cells through overexpression of T cell factor 1.

Frontiers in immunology·2025

Related Experiment Video

Updated: Jun 10, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Targeted cellular immunotherapy for leukemia patients.

Rosaely Casalegno-Garduño1, Anita Schmitt, Xinchao Wang

  • 1Department of Internal Medicine III, University Clinic Rostock, Rostock, Germany.

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
|August 4, 2010
PubMed
Summary

Targeted leukemia therapies use leukemia-associated antigens (LAAs) to guide specific T lymphocytes. This approach enables T cells to recognize and destroy leukemic blasts, offering a promising avenue for immunotherapy.

More Related Videos

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Related Experiment Videos

Last Updated: Jun 10, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Leukemia-associated antigens (LAAs) are differentially expressed on leukemic cells, making them targets for immunotherapy.
  • Specific T lymphocytes, particularly CD8(+) T cells with particular T cell receptors (TCRs), can recognize these LAAs.

Purpose of the Study:

  • To explore the potential of antigen-specific T cells for targeted leukemia therapy.
  • To highlight the role of streptamer technology in selecting and expanding these T cells for clinical application.

Main Methods:

  • Identification of leukemia-associated antigens (LAAs).
  • Selection of antigen-specific T cells using streptamers.
  • Good Manufacturing Practice (GMP)-certified T cell sorting technology.

Main Results:

  • Leukemia-associated antigens (LAAs) can elicit immune responses in leukemia patients.
  • CD8(+) T cells expressing specific T cell receptors (TCRs) recognize LAAs.
  • Streptamer-based selection allows for the isolation of functional antigen-specific T cells.

Conclusions:

  • Antigen-specific T cells, selected via streptamers, can be infused into patients to target and lyse leukemic blasts.
  • Adoptive T cell transfer represents a viable strategy to restore anti-leukemia immune responses, especially in immunocompromised patients.
  • Streptamer technology is the only GMP-certified method for antigen-specific T cell sorting currently available.